Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar
Mandate

Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar

November 30, 2016

Vinge has advised Vostok New Ventures Ltd (”Vostok”) in connection with an investment in the Paris based ride-sharing service Comuto SA (”BlaBlaCar”).

The acquisition was made by an issue in kind where the purchase price for the shares in BlaBlaCar consisted of 4,154,495 newly issued shares in Vostok. A prospectus for listing of the Swedish depository receipts representing the issued shares was approved by the Swedish Financial Supervisory Authority and made public on 23 November, 2016. The Swedish depository receipts were admitted to trading on Nasdaq Stockholm on 25 November 2016.

Vostok is an investment company with a special focus on online marketplaces and businesses with strong network effects. As of 30 September 2016, the net asset value of the group was USD 632.44 million. The Swedish depository receipts of Vostok are listed on Nasdaq Stockholm, Mid Cap segment.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Frida Bäckegren, Joel Wahlberg and Sara Osman.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025